CR11152A - Metodos y composiciones para el tratamiento de enfermedades alergicas - Google Patents

Metodos y composiciones para el tratamiento de enfermedades alergicas

Info

Publication number
CR11152A
CR11152A CR11152A CR11152A CR11152A CR 11152 A CR11152 A CR 11152A CR 11152 A CR11152 A CR 11152A CR 11152 A CR11152 A CR 11152A CR 11152 A CR11152 A CR 11152A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
treatment
allergic diseases
antibodies
Prior art date
Application number
CR11152A
Other languages
English (en)
Inventor
Liqun Dong
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CR11152A publication Critical patent/CR11152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente invencion se dan a conocer anticuerpos que reconocen especificamente y antagonizan al receptor de TSLP humano, y metodos para emplear estos anticuerpos con el fin de tratar o aminorar las enfermedades o trastornos mediados por la senalizacion de TSLP.
CR11152A 2007-06-20 2009-12-09 Metodos y composiciones para el tratamiento de enfermedades alergicas CR11152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94520507P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
CR11152A true CR11152A (es) 2010-01-20

Family

ID=39846944

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11152A CR11152A (es) 2007-06-20 2009-12-09 Metodos y composiciones para el tratamiento de enfermedades alergicas

Country Status (20)

Country Link
US (1) US8101182B2 (es)
EP (1) EP2170957A1 (es)
JP (1) JP2010530233A (es)
KR (1) KR20100034015A (es)
CN (1) CN102027012A (es)
AR (1) AR067045A1 (es)
AU (1) AU2008265128A1 (es)
BR (1) BRPI0813725A2 (es)
CA (1) CA2691157A1 (es)
CL (1) CL2008001826A1 (es)
CO (1) CO6251325A2 (es)
CR (1) CR11152A (es)
EA (1) EA201000006A1 (es)
EC (1) ECSP099812A (es)
IL (1) IL202573A0 (es)
PE (1) PE20090768A1 (es)
TN (1) TN2009000529A1 (es)
TW (1) TW200918557A (es)
WO (1) WO2008155365A1 (es)
ZA (1) ZA200908711B (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
PL371773A1 (en) 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies
WO2012007495A1 (en) * 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
KR101221649B1 (ko) * 2010-11-01 2013-01-14 광주과학기술원 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법
UA119328C2 (uk) * 2013-08-09 2019-06-10 Астеллас Фарма Інк. Антитіло до тslp-рецептора людини
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
CN111840696B (zh) 2014-06-03 2022-12-20 安姆根有限公司 可控制药物递送系统和使用方法
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
WO2016065181A1 (en) 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr) 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
SG10202012778YA (en) 2015-12-18 2021-01-28 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
EP3592403B1 (en) 2017-03-06 2025-08-20 Amgen Inc. Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
ES3023742T3 (en) 2017-03-28 2025-06-03 Amgen Inc Plunger rod and syringe assembly system
WO2018201064A1 (en) 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MX2020001171A (es) 2017-08-01 2020-03-12 Amgen Inc Sistemas y metodos para realizar un ensayo de glicanos en tiempo real de una muestra.
ES2978396T3 (es) 2017-08-01 2024-09-11 Amgen Inc Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR102682705B1 (ko) * 2018-07-04 2024-07-05 고려대학교 세종산학협력단 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2019396614B2 (en) 2018-12-14 2025-07-10 Amgen Inc. System suitability method for use with protein concentration determination by slope
JP7483731B2 (ja) 2019-02-14 2024-05-15 アムジエン・インコーポレーテツド 試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
WO2020172293A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
US20230035363A1 (en) 2019-03-04 2023-02-02 Amgen Inc. In vivo reversibility of high molecular weight species
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
MX2023003164A (es) 2020-09-18 2023-05-04 Amgen Inc Metodos de procesamiento de una muestra para analisis de mapeo de peptidos.
EP4240747A1 (en) 2020-11-05 2023-09-13 Amgen Inc. Materials and methods for protein processing
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
EP4430174A1 (en) 2021-11-09 2024-09-18 Amgen Inc. Production of therapeutic proteins
TW202432601A (zh) 2022-11-07 2024-08-16 美商上游生物公司 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法
KR20260020485A (ko) 2023-06-14 2026-02-11 브리스톨-마이어스 스큅 컴퍼니 당단백질의 준실시간 시알산 정량화
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
ES2391124T3 (es) * 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
AU2003208888B2 (en) * 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
SI1651247T1 (sl) * 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1793856A2 (en) * 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
CA2635599C (en) * 2006-01-13 2014-06-17 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies

Also Published As

Publication number Publication date
AR067045A1 (es) 2009-09-30
BRPI0813725A2 (pt) 2014-12-30
EA201000006A1 (ru) 2010-10-29
EP2170957A1 (en) 2010-04-07
KR20100034015A (ko) 2010-03-31
TN2009000529A1 (en) 2011-03-31
TW200918557A (en) 2009-05-01
JP2010530233A (ja) 2010-09-09
AU2008265128A1 (en) 2008-12-24
CL2008001826A1 (es) 2009-02-20
US20090074747A1 (en) 2009-03-19
PE20090768A1 (es) 2009-07-09
US8101182B2 (en) 2012-01-24
IL202573A0 (en) 2011-08-01
CO6251325A2 (es) 2011-02-21
CN102027012A (zh) 2011-04-20
WO2008155365A1 (en) 2008-12-24
ECSP099812A (es) 2010-01-29
ZA200908711B (en) 2010-08-25
CA2691157A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CR11152A (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
AR122834A2 (es) Anticuerpos que se unen a il-4 y/o il-13 y sus usos
CO6551721A2 (es) Moduladores de cinasa novedosos
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
CO6612271A2 (es) Anticuerpos anti-cd40
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GT201200058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20110103A (es) Heteroarilos sustituidos
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
EA201270012A1 (ru) Сублингвальный апоморфин
DOP2010000368A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
BRPI0813966A8 (pt) Usos de mdl-1
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
MX2012000389A (es) Imidazoles fusionados y composiciones que los comprenden para el tratamiento de enfermedades parasitarias, tales como, por ejemplo, malaria.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
ECSP21082527A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)